Tamalunas, A. ; Wendt, A.* ; Springer, F.* ; Vigodski, V.* ; Trieb, M.* ; Eitelberger, N.* ; Poth, H.* ; Ciotkowska, A.* ; Rutz, B.* ; Hu, S.* ; Schulz, H.* ; Ledderose, S.* ; Rogenhofer, N.* ; Kolben, T.* ; Nößner, E. ; Stief, C.G.* ; Hennenberg, M.*
Immunomodulatory imide drugs inhibit human detrusor smooth muscle contraction and growth of human detrusor smooth muscle cells, and exhibit vaso-regulatory functions.
BIOMED. PHARMACOTHER. 177:117066 (2024)
BACKGROUND: The immunomodulatory imide drugs (IMiDs) thalidomide, lenalidomide and pomalidomide may exhibit therapeutic efficacy in the prostate. In lower urinary tract symptoms (LUTS), voiding and storage disorders may arise from benign prostate hyperplasia, or overactive bladder. While current therapeutic options target smooth muscle contraction or cell proliferation, side effects are mostly cardiovascular. Therefore, we investigated effects of IMiDs on human detrusor and porcine artery smooth muscle contraction, and growth-related functions in detrusor smooth muscle cells (HBdSMC). METHODS: Cell viability was assessed by CCK8, and apoptosis and cell death by flow cytometry in cultured HBdSMC. Contractions of human detrusor tissues and porcine interlobar and coronary arteries were induced by contractile agonists, or electric field stimulation (EFS) in the presence or absence of an IMID using an organ bath. Proliferation was assessed by EdU assay and colony formation, cytoskeletal organization by phalloidin staining, RESULTS: Depending on tissue type, IMiDs inhibited cholinergic contractions with varying degree, up to 50 %, while non-cholinergic contractions were inhibited up to 80 % and 60 % for U46619 and endothelin-1, respectively, and EFS-induced contractions up to 75 %. IMiDs reduced viable HBdSM cells in a time-dependent manner. Correspondingly, proliferation was reduced, without showing pro-apoptotic effects. In parallel, IMiDs induced cytoskeletal disorganization. CONCLUSIONS: IMiDs exhibit regulatory functions in various smooth muscle-rich tissues, and of cell proliferation in the lower urinary tract. This points to a novel drug class effect for IMiDs, in which the molecular mechanisms of action of IMiDs merit further consideration for the application in LUTS.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Wissenschaftlicher Artikel
Typ der Hochschulschrift
Herausgeber
Schlagwörter
Lower Urinary Tract Symptoms (luts) ; Bladder Smooth Muscle Cell Proliferation ; Bladder Smooth Muscle Contraction ; Lenalidomide ; Overactive Bladder (oab) ; Pomalidomide ; Thalidomide; Urinary-tract Symptoms; Thalidomide Analog; Bladder; Lenalidomide; Identification; Pomalidomide; Progression; Impairment; Management; Efficacy
Keywords plus
Sprache
englisch
Veröffentlichungsjahr
2024
Prepublished im Jahr
0
HGF-Berichtsjahr
2024
ISSN (print) / ISBN
1950-6007
e-ISSN
0753-3322
ISBN
Bandtitel
Konferenztitel
Konferzenzdatum
Konferenzort
Konferenzband
Quellenangaben
Band: 177,
Heft: ,
Seiten: ,
Artikelnummer: 117066
Supplement: ,
Reihe
Verlag
Elsevier
Verlagsort
Paris
Tag d. mündl. Prüfung
0000-00-00
Betreuer
Gutachter
Prüfer
Topic
Hochschule
Hochschulort
Fakultät
Veröffentlichungsdatum
0000-00-00
Anmeldedatum
0000-00-00
Anmelder/Inhaber
weitere Inhaber
Anmeldeland
Priorität
Begutachtungsstatus
Peer reviewed
POF Topic(s)
30203 - Molecular Targets and Therapies
Forschungsfeld(er)
Immune Response and Infection
PSP-Element(e)
G-502710-001
G-501760-002
Förderungen
Deutsche Forschungsgemeinschaft
Munich Clinician Scientist Program (MCSP)
Ferdinand Eisenberger-Forschungsstipendium der DGU
LMU Munich's Medical Faculty Forderprogramm fuer Forschung und Lehre
Copyright
Erfassungsdatum
2024-07-19